Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort
- 30 June 2008
- journal article
- research article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 121 (6), 532-538
- https://doi.org/10.1016/j.amjmed.2008.02.018
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practiceAnnals Of The Rheumatic Diseases, 2007
- Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.2004
- Results from controlled clinical trials: how relevant for clinical practice?2003
- Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.2003
- The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient studyRheumatology, 2003
- Eligibility of patients in routine care for major clinical trials of anti–tumor necrosis factor α agents in rheumatoid arthritisArthritis & Rheumatism, 2003
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern SwedenAnnals Of The Rheumatic Diseases, 2002
- Selection of Patients may Limit the Generalizability of Results from Cancer TrialsActa Oncologica, 2002
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999